Brodalumab Shows Promise in Axial Spondyloarthritis

NEW YORK (Reuters Health) – Brodalumab may be a potential therapeutic option for patients with axial spondyloarthritis (axSpA), according to interim results of a phase-3 study. Brodalumab, which selectively inhibits interleukin-17 receptor A (IL-17RA), is approved for the treatment of plaque psoriasis in North America, Canada, Europe, Japan and other…